Pharmacokinetics and monitoring of cyclosporine following orthotopic liver transplantation.
Pharmacokinetics and monitoring of cyclosporine following orthotopic liver transplantation.
复制标题
原位肝移植后环孢素的药代动力学和监测。
DOI：
10.1055/s-2008-1040633
复制
发表时间：
1985
影响因子：
4.2
通讯作者：
Ptachcinski,RJ
中科院分区：
文献类型：
--
作者：
Venkataramanan,R;Burckhart,GJ;Ptachcinski,RJ
环孢霉素是一种新型的免疫抑制剂，它是从灵芝和胀囊弯颈霉中分离得到的。该化合物的免疫抑制活性于1976年首次报道，1978年开始临床试验。自首次临床试验以来，环孢素已被证明是一种有效的免疫抑制剂，无骨髓毒性。这导致环孢霉素作为免疫抑制剂的广泛使用，并导致器官移植成功率的提高。然而，对环孢霉素的反应存在显著的患者间差异。其独特的结构特性及其可变的药代动力学特征可能有助于此类观察结果。美国食品和药物管理局批准这种药物用于某些器官移植患者，并建议在这些患者中定期监测环孢素的血液或血浆浓度。最佳的治疗监测方案应包括环孢素的血液或血浆浓度分析，这应与其他临床，生化和免疫学测量解释。本文的目的是提供一个总结环孢素在原位肝移植（奥尔特）患者的药代动力学和治疗监测。
Cyclosporine is a novel immunosuppressant derived from two strains of fungi, Cylindrocarpon lucidum and Tolypocladium inflatum~ ams.~ The immunosuppressive activity of this compound was first reported in 1976,~ and clinical trials were initiated in 1978. Since its first clinical trial, cyclosporine has proved to be a potent immunosuppressant without myelotoxicity. This has led to the extensive use of cyclosporine as an immunosuppressant and has resulted in improved success of organ transplantation. There is, however, a significant interpatient variability in response to cyclosporine. Its unique structural properties and its variable pharmacokinetic profile may contribute to such observations. The Food and Drug Administration approved this drug for use in certain organ transplant patients, with a recommendation that blood or plasma concentrations of cyclosporine should be monitored routinely in these patients. An optimal therapeutic monitoring program should incorporate an analysis of blood or plasma concentration of cyclosporine, which should be interpreted with other clinical, biochemical, and immunologic measurements. The objective of this article is to provide a summary of the pharmacokinetics and therapeutic monitoring of cyclosporine in orthotopic liver transplant (OLT) patients.